Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 9 |
| 1.1 List of Tables | 7 | 2 |
| 1.2 List of Figures | 9 | 4 |
| 2 Global Metabolic Disorders Therapeutics Market: Introduction | 13 | 2 |
| 2.1 GBI Research Report Guidance | 13 | 2 |
| 3 Global Metabolic Disorders Therapeutics Market: Market Overview | 15 | 15 |
| 3.1 Introduction | 15 | 1 |
| 3.2 Revenue Forecasts for the Global Metabolic Disorders Therapeutics Market | 15 | 1 |
| 3.2.1 Sales Value | 15 | 1 |
| 3.2.2 Sales Volume | 16 | 1 |
| 3.2.3 Annual Cost of Therapy | 17 | 2 |
| 3.2.4 Treatment Usage Patterns | 19 | 1 |
| 3.2.4.1 Diseased Population | 20 | 1 |
| 3.2.4.2 Treatment Seeking Population | 20 | 1 |
| 3.2.4.3 Diagnosed Population | 21 | 1 |
| 3.2.4.4 Prescription Population | 22 | 1 |
| 3.2.5 Generics Share in the Global Metabolic Disorders Therapeutics Market | 23 | 2 |
| SWOT Analysis | 25 | 1 |
| 3.3.1 Strength | 25 | 1 |
| 3.3.1.1 Significant Growth in Metabolic Disorders Diseased Population is the Greatest Strength to the Global Metabolic Disorders Market | 25 | 1 |
| 3.3.1.2 Drug Treatment is One of the Key Treatment Options Available for Diabetes Patients | 25 | 1 |
| 3.3.1.3 Metabolic Disorders R&D Pipeline though is Weak, a Few First-in-class Drugs in Late-stage Development will Bolster the Future Growth of the Market | 25 | 1 |
| 3.3.2 Weakness | 26 | 1 |
| 3.3.2.1 Poor Patient Compliance of Insulin Injections, Oral Antidiabetic Drugs Such as Avandia, and Anti-obesity Drugs such as Meredia Proved Detrimental to the Growth of Metabolic Disorders Market | 26 | 1 |
| 3.3.3 Opportunity | 26 | 1 |
| 3.3.3.1 High Unmet Needs Still Exist in the Metabolic Disorders Market and Drugs with Modest Efficacy and High Safety Profile will have the Opportunity to Become Future Potential Blockbuster | 26 | 1 |
| 3.3.3.2 Disease Awareness Campaigns Reinforce the Growth of Diagnosed Population Percentage | 26 | 1 |
| 3.3.4 Threat | 26 | 1 |
| 3.3.4.1 Recent Findings of Anti-diabetic Drugs Potential Side-effects Forced FDA to Tighten Drug Approvals | 26 | 1 |
| 3.3.4.2 Unfavorable Reimbursement Coverage in Major Countries Poses Grave Threat to the Growth of Metabolic Disorders Market | 26 | 1 |
| 3.4 Metabolic Disorders Therapeutics Market Drivers | 27 | 1 |
| 3.4.1 High Unmet Needs in the Obesity Market Create a Huge Market Opportunity for Future Potential Blockbusters | 27 | 1 |
| 3.4.2 Drastic Raise in Metabolic Disorders Diseased Population in the Developed Countries | 27 | 1 |
| 3.4.3 Technological Advances in the Diabetic Therapies Market are expected to Enhance Patient Acceptability and Therefore Patient-base | 28 | 1 |
| 3.4.4 Sedentary Life Styles and Increased Consumption of Fat-rich Products Driving the Growth of Metabolic Disorders Diseased Population | 28 | 1 |
| 3.5 Metabolic Disorders Therapeutics Market Restraints | 28 | 1 |
| 3.5.1 Severe Side-effects Associated with Metabolic Disorder Drugs are Proving Detrimental to the Growth of the Market | 28 | 1 |
| 3.5.2 Lack of Proper Reimbursement Coverage in Countries such as Germany and France Restraining the Growth of the Market | 29 | 1 |
| 3.5.3 Generics Pose Significant Threat to the Global Metabolic Disorders Therapeutics Market | 29 | 1 |
| 4 Global Metabolic Disorders Therapeutics Market: Therapeutic Landscape | 30 | 31 |
| 4.1 Diabetes Market | 30 | 1 |
| 4.1.1 Introduction | 30 | 1 |
| 4.1.2 Unmet Needs | 30 | 1 |
| 4.1.2.1 Some of the Anti-diabetic Drugs Carry Cardiovascular Risks | 30 | 1 |
| 4.1.2.2 Insulin Delivery Systems Carry Poor Patients Compliance | 30 | 1 |
| Use of Insulin Analogues might trigger Carcinogenic Effects in the Body | 31 | 1 |
| 4.1.3 Sales Value | 31 | 1 |
| 4.1.4 Sales Volume | 32 | 1 |
| 4.1.5 Annual Cost of Therapy | 33 | 2 |
| Treatment Usage Patterns | 35 | 1 |
| 4.1.6.1 Diseased Population | 36 | 1 |
| 4.1.6.2 Treatment Seeking Population | 37 | 1 |
| 4.1.6.3 Diagnosed Population | 37 | 1 |
| 4.1.6.4 Prescription Population | 38 | 1 |
| 4.1.7 Geographical Segmentation | 39 | 3 |
| 4.1.8 Generics Share in the Global Diabetes Market | 42 | 3 |
| Drivers of Diabetes Market | 45 | 1 |
| 4.1.9.1 Ageing, Deskbound Lifestyles and Increased Consumption of Junk Food are the Driving Forces of Metabolic Disorders Prevalence | 45 | 1 |
| 4.1.9.2 Diabetes on the Rise in U.S | 45 | 1 |
| 4.1.9.3 New First-in-class Drugs in Early Stage Clinical development | 45 | 1 |
| 4.1.9.4 Diabetes Awareness Campaigns Directed at Educating Patients, are Driving the Treatment Seeking Population | 46 | 1 |
| 4.1.10 Restraints of Diabetes Market | 46 | 1 |
| 4.1.10.1 Cardiovascular Side Effects Affecting Prescription Sales of Diabetes Drugs | 46 | 1 |
| 4.1.10.2 Patent Expiry of Blockbusters such as Actos, Starlix and Avandia is Expected to Restrain the Growth of the Global Diabetes Market | 46 | 1 |
| 4.2 Obesity Market | 46 | 1 |
| 4.2.1 Introduction | 46 | 1 |
| 4.2.2 Sales Value | 46 | 2 |
| 4.2.3 Sales Volume | 48 | 1 |
| 4.2.4 Annual Cost of Therapy | 49 | 1 |
| 4.2.5 Treatment Usage Patterns | 50 | 1 |
| 4.2.5.1 Diseased Population | 51 | 1 |
| 4.2.5.2 Treatment Seeking Population | 52 | 1 |
| 4.2.5.3 Diagnosed Population | 52 | 1 |
| 4.2.5.4 Prescription Population | 53 | 1 |
| 4.2.6 Geographical Segmentation | 54 | 3 |
| 4.2.7 Generics Share in the Global Obesity Market | 57 | 2 |
| 4.2.8 Drivers of Obesity Market | 59 | 1 |
| 4.2.8.1 High Unmet Needs Exist in the Obesity Market and Therefore, Any Drug That Can Manage to Pass through FDA Approval will be a Blockbuster | 59 | 1 |
| 4.2.8.2 Rapidly Growing Obesity Population in Major Countries Driving the Growth of the Anti-Obesity Drugs Market | 60 | 1 |
| 4.2.9 Restraints of Obesity Market | 60 | 1 |
| 4.2.9.1 Side-effects associated with anti-obesity drugs are very high | 60 | 1 |
| 4.2.9.2 Refusal by Healthcare Authorities to Grant Reimbursement to Anti-obesity Drugs has Impeded Growth | 60 | 1 |
| 4.2.9.3 Availability of other Non-therapeutic Treatments such as herbal treatment and weight-loss treatments detrimental to the growth of the global obesity market | 60 | 1 |
| 5 Global Metabolic Disorders Therapeutics Market: Geographical Landscape | 61 | 25 |
| 5.1 Geographical Break-up | 61 | 3 |
| 5.2 The US | 64 | 1 |
| 5.2.1 Sales Value | 64 | 1 |
| 5.2.2 Sales Volume | 65 | 1 |
| 5.2.3 Annual Cost of Therapy | 66 | 1 |
| 5.2.4 Treatment Usage Patterns | 67 | 1 |
| 5.2.4.1 Diseased Population | 68 | 1 |
| 5.2.4.2 Treatment Seeking Population | 68 | 1 |
| 5.2.4.3 Diagnosed Population | 69 | 1 |
| 5.2.4.4 Prescription Population | 70 | 1 |
| 5.3 Top Five Countries in Europe | 71 | 1 |
| 5.3.1 Sales Value | 71 | 1 |
| 5.3.2 Sales Volume | 72 | 1 |
| 5.3.3 Annual Cost of Therapy | 73 | 1 |
| 5.3.4 Treatment Usage Patterns | 74 | 1 |
| 5.3.4.1 Diseased Population | 75 | 1 |
| 5.3.4.2 Treatment Seeking Population | 76 | 1 |
| 5.3.4.3 Diagnosed Population | 77 | 1 |
| 5.3.4.4 Prescription Population | 78 | 1 |
| 5.4 Japan | 79 | 1 |
| 5.4.1 Sales Value | 79 | 1 |
| 5.4.2 Sales Volume | 80 | 1 |
| 5.4.3 Annual Cost of Therapy | 81 | 1 |
| 5.4.4 Treatment Usage Patterns | 82 | 1 |
| Diseased Population | 83 | 1 |
| 5.4.4.2 Treatment Seeking Population | 83 | 1 |
| 5.4.4.3 Diagnosed Population | 84 | 1 |
| 5.4.4.4 Prescription Population | 85 | 1 |
| 6 Global Metabolic Disorders Therapeutics Market: Pipeline Analysis | 86 | 14 |
| 6.1 Introduction | 86 | 1 |
| 6.1.1 Research and Development Pipeline - Diabetes | 87 | 2 |
| 6.1.1.1 Type 1 Diabetes | 89 | 2 |
| 6.1.1.2 Type 2 Diabetes | 91 | 1 |
| 6.1.2 Research and Development Pipeline - Obesity | 91 | 3 |
| 6.2 R&D Trends | 94 | 1 |
| 6.2.1 New Promising Treatments for Diabetic Retinopathy | 94 | 1 |
| 6.2.2 Identifying Biomarkers will Mark an Important Step in Metabolic Disorders R&D | 94 | 1 |
| 6.2.3 Combination Drugs is an Important Part of Diabetes and Obesity Pipeline | 94 | 1 |
| 6.2.4 First-in-class Insulin Pills (Oral Delivery) in Development | 94 | 1 |
| 6.3 New Drug Insulin Delivery Systems | 95 | 1 |
| 6.3.1 Altea Therapeutics Transdermal Passport System | 95 | 1 |
| 6.3.1.1 Introduction | 95 | 1 |
| 6.3.1.2 Mode of Delivery | 95 | 1 |
| 6.3.1.3 Impact | 95 | 1 |
| 6.3.2 Technosphere/Insulin Mimics Early Post-Prandial Insulin Release | 95 | 1 |
| 6.3.2.1 Introduction | 95 | 1 |
| 6.3.2.2 Mode of Delivery | 95 | 1 |
| 6.3.2.3 Impact | 96 | 1 |
| 6.4 Profiles of Key Late-Stage Drugs in the Diabetes Market | 96 | 1 |
| 6.4.1 Teplizumab | 96 | 1 |
| 6.4.1.1 Introduction | 96 | 1 |
| 6.4.1.2 Mechanism of Action | 96 | 1 |
| 6.4.1.3 Clinical Trial Management | 96 | 1 |
| 6.4.2 Oral-Lyn | 96 | 1 |
| 6.4.2.1 Introduction | 96 | 1 |
| 6.4.2.2 Mechanism of Action | 97 | 1 |
| 6.4.2.3 Clinical Trial Management | 97 | 1 |
| 6.4.3 Liraglutide for Diabetes | 97 | 1 |
| 6.4.3.1 Introduction | 97 | 1 |
| 6.4.3.2 Mechanism of Action | 97 | 1 |
| 6.4.3.3 Clinical Trial Management | 97 | 1 |
| 6.5 Profiles of Key Late-Stage Drugs in the Obesity Market | 98 | 1 |
| 6.5.1 Lorcaserin | 98 | 1 |
| 6.5.1.1 Introduction | 98 | 1 |
| 6.5.1.2 Mechanism of Action | 98 | 1 |
| 6.5.1.3 Clinical Trial Management | 98 | 1 |
| 6.5.2 Contrave | 99 | 1 |
| 6.5.2.1 Introduction | 99 | 1 |
| 6.5.2.2 Mechanism of Action | 99 | 1 |
| 6.5.2.3 Clinical Trial Management | 99 | 1 |
| 6.5.3 Liraglutide for Obesity | 99 | 1 |
| 6.5.3.1 Introduction | 99 | 1 |
| 6.5.3.2 Mechanism of Action | 99 | 1 |
| 6.5.3.3 Clinical Trial Management | 99 | 1 |
| 7 Global Metabolic Disorders Therapeutics Market: Competitive Landscape | 100 | 29 |
| 7.1 Diabetes Market Overview | 100 | 2 |
| 7.2 Market Share Analysis: Diabetes Therapeutics | 102 | 1 |
| 7.3 Obesity Market Overview | 103 | 2 |
| 7.4 Market Share Analysis: Obesity Therapeutics | 105 | 1 |
| 7.5 Competitive Profiling | 106 | 1 |
| 7.5.1 Diabetes Therapeutics Market | 106 | 1 |
| 7.5.2 Obesity Therapeutics Market | 107 | 1 |
| 7.5.3 Human Insulin Products and Oral Antidiabetic Drugs Like Actos Group (Actos and Actoplus met) and Lantus Have Led Market Growth | 108 | 1 |
| 7.5.4 Novo Nordisk | 109 | 1 |
| 7.5.4.1 Product Portfolio | 110 | 1 |
| 7.5.4.2 Product Pipeline | 111 | 1 |
| 7.5.5 Sanofi-aventis | 111 | 2 |
| 7.5.5.1 Product Portfolio | 113 | 1 |
| 7.5.5.2 Product Pipeline | 114 | 1 |
| 7.5.6 Takeda | 114 | 1 |
| 7.5.6.1 Product Portfolio | 115 | 1 |
| 7.5.6.2 Product Pipeline | 115 | 1 |
| 7.5.7 Eli Lilly | 115 | 1 |
| 7.5.7.1 Product Portfolio | 116 | 1 |
| 7.5.7.2 Product Pipeline | 117 | 1 |
| 7.5.8 GlaxoSmithKline (GSK) | 118 | 2 |
| 7.5.8.1 Product Portfolio | 120 | 1 |
| 7.5.8.2 Product Pipeline | 121 | 1 |
| 7.5.9 Merck &Co Inc | 121 | 1 |
| 7.5.9.1 Product Portfolio | 122 | 1 |
| 7.5.9.2 Product Pipeline | 123 | 1 |
| 7.5.10 Amylin Pharmaceuticals | 123 | 1 |
| 7.5.10.1 Product Portfolio | 124 | 1 |
| 7.5.10.2 Product Pipeline | 125 | 1 |
| 7.5.11 Roche | 125 | 1 |
| 7.5.11.1 Product Portfolio | 126 | 1 |
| 7.5.11.2 Pipeline Product | 126 | 1 |
| 7.5.12 Abbott | 127 | 1 |
| 7.5.12.1 Product Portfolio | 128 | 1 |
| 7.5.12.2 Product Pipeline | 128 | 1 |
| 8 Global Metabolic Disorders Therapeutics Market: Strategic Consolidations | 129 | 14 |
| 8.1 Overview | 129 | 1 |
| 8.1.1 Ligand Pharmaceuticals Acquired Metabasis Therapeutics in October 2009 | 130 | 1 |
| 8.1.2 CombinatoRx, Inc. Acquired Neuromed Pharmaceuticals, Inc. in August 2009 | 131 | 1 |
| 8.1.3 Mylan Laboratories Acquired Matrix Laboratories Limited in March 2009 | 131 | 1 |
| 8.1.4 Pfizer Acquired Wyeth in January 2009 | 131 | 1 |
| 8.1.5 Wyeth Acquired Thiakis Ltd. in December 2008 | 131 | 1 |
| 8.1.6 Bellus Health Inc. Acquired Innodia Inc in July 2008 | 131 | 1 |
| 8.1.7 GlaxoSmithKline Acquired Sirtris Pharmaceuticals in April 2008 | 131 | 1 |
| 8.1.8 Point Therapeutics and Dara Biosciences Merged in February 2008 | 132 | 1 |
| 8.1.9 Teva Pharmaceutical Industries Acquired Cogenesys, Inc. in January 2008 | 132 | 1 |
| 8.2 R&D Licensing Agreements | 132 | 1 |
| 8.2.1 Deals by Indication | 132 | 1 |
| 8.2.2 Deals by Phase | 133 | 1 |
| 8.2.3 Deals by Geography | 133 | 1 |
| 8.2.4 Deals by Licensing Type | 134 | 1 |
| 8.2.5 Deals by Value ($) | 135 | 1 |
| 8.2.6 Preclinical | 136 | 1 |
| Verva FGFR Portfolio | 136 | 1 |
| 8.2.6.2 Debio 0930 | 136 | 1 |
| 8.2.6.3 DGAT1 Program | 137 | 1 |
| 8.2.6.4 Organix 5-HT2C Agonists | 137 | 1 |
| 8.2.6.5 Telik Insulin Receptor Activators | 137 | 1 |
| 8.2.6.6 MT 39 series | 137 | 1 |
| 8.2.6.7 MKG02 | 137 | 1 |
| 8.2.6.8 Gal/Merck Obesity &Diabetes Program | 137 | 1 |
| 8.2.6.9 Glucagon Targeted Therapies | 137 | 1 |
| 8.2.7 Phase I | 138 | 1 |
| Exenatide Transdermal Formulation | 138 | 1 |
| 8.2.8 Phase II | 138 | 1 |
| 8.2.8.1 Davalintide and Pramlintide | 138 | 1 |
| 8.2.8.2 PN2034 | 138 | 1 |
| BHT-3021 | 139 | 1 |
| 8.2.8.4 SK-0403 | 139 | 1 |
| 8.2.8.5 TT-223 | 139 | 1 |
| 8.2.9 Phase III | 139 | 1 |
| 8.2.9.1 Dutogliptin tartrate (PHX1149) | 140 | 1 |
| 8.2.9.2 Oral-lyn with Dongsung Pharmaceutical | 140 | 1 |
| 8.2.9.3 Oral-lyn with Scigen Limited | 140 | 1 |
| 8.2.10 Approved | 140 | 1 |
| Galvus and Eucreas | 141 | 1 |
| 8.2.10.2 SciLin | 141 | 1 |
| 8.2.10.3 Gliconorm | 141 | 1 |
| 8.2.10.4 Glipizide + Metformin HCl | 141 | 1 |
| 8.2.10.5 Januvia | 141 | 1 |
| 8.2.10.6 Glumetza | 142 | 1 |
| 9 Global Metabolic Disorders therapeutics Market: Appendix | 143 | 6 |
| 9.1 Market Definitions | 143 | 1 |
| 9.2 Abbreviations | 143 | 1 |
| 9.3 Research Methodology | 144 | 4 |
| 9.3.1 Coverage | 144 | 1 |
| 9.3.2 Secondary Research | 145 | 1 |
| 9.3.3 Primary Research | 145 | 1 |
| 9.3.4 Forecasts | 145 | 1 |
| 9.3.4.1 Epidemiology-based Forecasting | 145 | 2 |
| 9.3.5 Expert Panel Validation | 147 | 1 |